三联疗法防治原发性肝癌切除术后复发临床观察  

Clinical Observation on Triple Therapy in the Prevention and Treatment of Recurrence of Primary Liver Cancer after Hepatectomy

作　　者：陈文林 范湘旭 梁芳 吕锦珍 张云城 冉云 杨大国[2] CHEN Wenlin;FAN Xiangxu;LIANG Fang;LYU Jinzhen;ZHANG Yuncheng;RAN Yun;YANG Daguo(Department of Hepatology,Shenzhen Hospital(Longgang),Beijing University of Chinese Medicine,Guangdong Province,Shenzhen 518172,China;Department of Hepatology,the Third People’s Hospital of Shenzhen,Guangdong Province,Shenzhen 518112,China)

机构地区：[1]北京中医药大学深圳医院(龙岗)肝病科,广东深圳518172 [2]深圳市第三人民医院肝病科,广东深圳518112

出　　处：《光明中医》2022年第16期2949-2951,2994,共4页GUANGMING JOURNAL OF CHINESE MEDICINE

基　　金：深圳市科技创新计划项目(NO.JCYJ20180302150216419)。

摘　　要：目的初步探讨胸腺法新联合康莱特注射液及中药正肝方随症加减三联疗法在预防原发性肝癌术后复发的临床疗效。方法将60例原发性肝癌术后患者随机分为对照组和观察组,对照组予常规抗病毒治疗,观察组在对照组的基础上予注射用胸腺法新、康莱特及中药正肝方随症加减的“三联疗法”治疗。2组疗程均为6个月,随访18月,并且每3月复查患者肝功能、甲胎蛋白(AFP)、T淋巴细胞免疫功能,治疗后评估中医证候积分和生活质量评分,观察2组的临床疗效和复发率。结果观察组治疗后证候总积分、生活质量评分显著低于对照组,差异有统计学意义(P<0.05);观察组CD8细胞升高优于对照组,差异有统计学意义(P<0.05);1年后随访观察组的复发率明显低于对照组,观察组总有效率显著高于对照组,差异有统计学意义(P<0.05)。结论胸腺法新联合康莱特注射液及中药正肝方随症加减三联疗法能显著改善患者临床症状和提高其生活质量,促进肝功能改善,调节免疫功能,降低AFP水平,而且具有复发率低,疗效显著的优势,值得进一步推广应用。Objective To investigate the clinical effect of Thymalfasin injection combined with Kanglaite injection and Chinese medicine Zhenggan prescription in the prevention of postoperative recurrence of primary liver cancer.Methods Sixty patients with primary liver cancer were randomly divided into control group and observation group.The control group was treated with conventional antiviral therapy,and the observation group was treated with“triple therapy”of Thymalfasin injection combined with Kanglaite injection and Chinese medicine Zhenggan prescription.The treatment course of both groups was 6 months,followed up for 18 months,and the liver function,AFP and Tlymphocyte immune function of the patients were reviewed every 3 months.Traditional Chinese medicine syndrome score and quality of life score were evaluated after treatment,and the clinical effect and recurrence rate of the two groups were observed.Results The total syndrome score and quality of life score in the observation group were significantly lower than those in the control group after treatment,and the difference had statistical significance(P<0.05).The increase of CD8 cells in the observation group was better than those in the control group,and the difference was statistically significant(P<0.05).After one year of following-up,the recurrence rate of the observation group was significantly lower than that of the control group,the total effective rate of the observation group was significantly higher than that of the control group,and the difference had statistical significance(P<0.05).Conclusion The triple therapy of Thymalfasin injection combined with Kanglaite injection and Chinese medicine Zhenggan prescription can significantly improve patients’clinical syndrome and quality of life,promote the improvement of liver function,regulate immune function,reduce AFP level,has the advantages of low recurrence rate,has significant curative effect,and is worthy of further promotion and application.

关 键 词：癥积 原发性肝癌 胸腺法新 康莱特 正肝方 肿瘤复发 

分 类 号：R735.7[医药卫生—肿瘤]